Linezolid treatment of total prosthetic knee infection due to methicillin-resistant Staphylococcus epidermidis [1]

Journal of Infection

Volumn 47, Issue 1, 2003, Pages 87-88

  Jover Sáenz, Alfredo ^a   Barcenilla Gaite, Fernando ^a   Gómez Ribelles, Antonio ^a   Porcel Pérez, José M ^a   Garrido Calvo, Sonia ^b  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; COTRIMOXAZOLE; GLYCOPEPTIDE; LINEZOLID; METICILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; CASE REPORT; DEBRIDEMENT; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; KNEE ARTHRITIS; LETTER; PENICILLIN RESISTANCE; PROSTHESIS INFECTION; SKIN TOXICITY; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STOMACH DISEASE; TOTAL KNEE REPLACEMENT; VERTIGO;

EID: 0038157027     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(03)00019-7     Document Type: Letter

References (10)

1. Muñoz P, Bouza E. Acute and chronic adult osteomyelitis and prosthesis related infections. Balliére's Clinical Rheumatology 1999;13:129-148.
2. Mader JT, Wang J, Calhoun JH. Antibiotic therapy for musculoskeletal infections. J Bone Joint Surg Am 2001;83: 1878-1890.
3. Hanssen AD, Rand JA. An instructional course lecture. The American academy of orthopaedic surgeons. Evaluation at treatment of infections at the site of a total hip or knee arthroplasty. J Bone Joint Surg Am 1998;80:910-922.
4. Brause BD. Infecciones en huesos y articulaciones con prótesis. In: Mandell GL, Bennet JE, Dolin R, editors. Principios y práctica en enfermedades infecciosas, 5th edn. Montevideo: Libermed; 2002. p. 1451-1456.
5. Barrett JF. Linezolid Pharmacia Corp. Curr Opin Invest Drugs 2000;1:181-187.
6. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45:1843-1846.
7. Clementt D, Markham A. Linezolid Drugs 2000;59:815-827.
8. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001;285:1291.
9. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001;61:525-551.
10. Bouza E, Muñoz P. Posibles indicaciones futuras de linezolid. Enferm Infect Microbiol Clin 2002;1:54-58.